Multimodal prognosis of negative symptom severity in individuals at increased risk of developing psychosis
Schmidt André; Salokangas Raimo KR; Pantelis Christos; Chisholm Katharine; Kambeitz Joseph; Hietala Jarmo; Sanfelici Rachele; Radua Joaquin; Riecher-Rossler Anita; Wood Stephen J; Dwyer Dominic B; Hauke Daniel J; Meisenzahl Eva; Ruhrmann Stephan; Rosen Marlene; Haas Shalaila S; Studerus Erich; Antonucci Linda A; Brambilla Paolo; Kambeitz-Ilankovic Lana; Schultze-Lutter Frauke; Upthegrove Rachel; Borgwardt Stefan; The Pronia Group; Ruef Anne; Koutsouleris Nikolaos; Penzel Nora; Lalousis Paris A; Lichtenstein Theresa; Andreou Christina
Multimodal prognosis of negative symptom severity in individuals at increased risk of developing psychosis
Schmidt André
Salokangas Raimo KR
Pantelis Christos
Chisholm Katharine
Kambeitz Joseph
Hietala Jarmo
Sanfelici Rachele
Radua Joaquin
Riecher-Rossler Anita
Wood Stephen J
Dwyer Dominic B
Hauke Daniel J
Meisenzahl Eva
Ruhrmann Stephan
Rosen Marlene
Haas Shalaila S
Studerus Erich
Antonucci Linda A
Brambilla Paolo
Kambeitz-Ilankovic Lana
Schultze-Lutter Frauke
Upthegrove Rachel
Borgwardt Stefan; The Pronia Group
Ruef Anne
Koutsouleris Nikolaos
Penzel Nora
Lalousis Paris A
Lichtenstein Theresa
Andreou Christina
SpringerNature
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2021093048121
https://urn.fi/URN:NBN:fi-fe2021093048121
Tiivistelmä
Negative symptoms occur frequently in individuals at clinical high risk (CHR) for psychosis and contribute to functional impairments. The aim of this study was to predict negative symptom severity in CHR after 9 months. Predictive models either included baseline negative symptoms measured with the Structured Interview for Psychosis-Risk Syndromes (SIPS-N), whole-brain gyrification, or both to forecast negative symptoms of at least moderate severity in 94 CHR. We also conducted sequential risk stratification to stratify CHR into different risk groups based on the SIPS-N and gyrification model. Additionally, we assessed the models' ability to predict functional outcomes in CHR and their transdiagnostic generalizability to predict negative symptoms in 96 patients with recent-onset psychosis (ROP) and 97 patients with recent-onset depression (ROD). Baseline SIPS-N and gyrification predicted moderate/severe negative symptoms with significant balanced accuracies of 68 and 62%, while the combined model achieved 73% accuracy. Sequential risk stratification stratified CHR into a high (83%), medium (40-64%), and low (19%) risk group regarding their risk of having moderate/severe negative symptoms at 9 months follow-up. The baseline SIPS-N model was also able to predict social (61%), but not role functioning (59%) at above-chance accuracies, whereas the gyrification model achieved significant accuracies in predicting both social (76%) and role (74%) functioning in CHR. Finally, only the baseline SIPS-N model showed transdiagnostic generalization to ROP (63%). This study delivers a multimodal prognostic model to identify those CHR with a clinically relevant negative symptom severity and functional impairments, potentially requiring further therapeutic consideration.
Kokoelmat
- Rinnakkaistallenteet [19207]